Stock LYTIX LYTIX BIOPHARMA
Add to a list
To use this feature you must be a member
Log inSign up

All News Lytix Biopharma

Equities

LYTIX

NO0010405780

Market Closed - Oslo Bors
Other stock markets
 15:45:00 16/05/2024 BST 		5-day change 1st Jan Change
5.6 NOK -10.83% Intraday chart for Lytix Biopharma +2.19% +15.23%
04-25 Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity CI
04-10 Lytix Biopharma to Raise Up to NOK55 Million via Share Offering MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lytix Biopharma - Minutes of Ordinary General Meeting
AQ
Lytix Biopharma AS - New share capital registered
AQ
Correction in the notice of Annual General Meeting in Lytix Biopharma AS
AQ
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024
AQ
Lytix Biopharma AS: Annual Report for 2023
AQ
Lytix Biopharma AS - Share issue pursuant to board authorisation
AQ
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates
AQ
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering
AQ
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
AQ
Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity
CI
Lytix Biopharma AS - Preliminary results in the share offering
AQ
Lytix Biopharma AS - Last day of the Application Period
AQ
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB
PU
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering
MT
Transcript : Lytix Biopharma AS, Q4 2023 Earnings Call, Feb 29, 2024
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy
MT
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology
CI
Transcript : Lytix Biopharma AS, Q3 2023 Earnings Call, Nov 09, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYTIX Stock
  4. News Lytix Biopharma